Executive Interview – Crescendo

Published on 18 October 2016

Crescendo Biologics, a Touchstone Innovations (AIM: IVO) investee company, is a Cambridge-based, cancer-focused drug discovery and development company with a proprietary transgenic VH mouse platform and rapid formatting capabilities that are used to create its therapeutic product candidates, Humabodies. Humabodies are built from fully human single-domain antibody VH fragments (heavy chain variable domain) generated by a proprietary triple knockout transgenic mouse (Crescendo mouse) and can be bispecific or multi-specific. Its initial focus is on the development of Humabody drug conjugates (HDCs) and multi-specific checkpoint modulators.

Read the full report

Share this with friends and colleagues